Lantheus Holdings LNTH Contingent Payments Under Companys License Agreements

Contingent Payments Under Companys License Agreements at other companies

PTC TherapeuticsPTCT

-$4.68M-941%

Riot Platforms, Inc.RIOT

$8.2M-47.2%

FlowserveFLS

$168.5K-95.5%

PTC TherapeuticsPTCT

$50M—

Apollo Global ManagementAPO

$56M+1.8%

InsmedINSM

$54.87M+350%

Other financials

Income statement

See full

Revenue$377.3M+1.2%

Gross profit$230.9M-2.9%

Operating income$81.3M-20.3%

Net income$118.4M+62.3%

EPS (diluted)$1.80+76.5%

Balance sheet

See full

Cash & equivalents$500.3M-46.8%

Total debt$627.9M+1.8%

Total equity$1.2B+4.1%

Total assets$2.3B+14.2%

Cash flow

See full

Operating cash flow$125.1M+16.3%

CapEx$3.2M-63.0%

Free cash flow$121.9M+23.3%

Valuation

See full

Market cap$6.76B-26.3%

Enterprise value$6.89B-20.5%

P/E24.2×-10.2×

P/S4.4×-1.6×

Profitability

See full

Gross margin60.5%-3.6pp

Operating margin18.8%-10.7pp

Net margin18%+0.7pp

FCF margin24.4%-6.4pp

Returns & leverage

See full

Return on equity23.5%-1.7pp

Debt / equity0.5×0.0×

Current ratio2.8×-2.9×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept lnth:ContingentPaymentsUnderCompanysLicenseAgreements.

The official record: Lantheus Holdings’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lantheus Holdings's contingent payments under companys license agreements.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lantheus Holdings's contingent payments under companys license agreements?: Lantheus Holdings (LNTH) reported contingent payments under companys license agreements of $4.9B in Q4 2025.
What does contingent payments under companys license agreements mean?: This metric tracks potential future payments tied to the achievement of specific milestones, such as regulatory approvals or commercial sales targets, within license agreements. It represents a form of off-balance-sheet risk that could impact future profitability if development or commercialization efforts succeed. Investors use this to assess the potential future cash outflows associated with the company's R&D and partnership pipeline.